Pain medications are essential for improving the care and outcomes for the 100 million adults living with chronic pain in the United States.
It is estimated that the cost of medical treatment and lost productivity associated with chronic pain is $560-$635 billion annually.
The abuse and misuse of prescription opioid drugs has reached epidemic proportions in the United States.
New formulations to make opioid drug that are resistant to tampering and abuse have failed to match the advances in new ways to abuse these drugs.
Most opioid drugs currently on the market can be physically manipulated (crushed, cut, grated, ground, heated, dissolved) to yield active opioid that can be injected, snorted, smoked, or chewed when taken orally.
TAAP and MPAR™ Platforms
Ensysce has seized on this problem and has developed highly novel TAAP pain products that remove the ability to abuse by snorting, extracting, injection or chewing. Our MPAR™ combination products provide overdose protection to all of the product pipeline.
TAAP abuse-resistant opioid prodrugs have the potential to meet the medical needs of patients living with chronic pain, while providing a solution to the national epidemic of prescription opioid abuse, limiting their use to oral administration.